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Summary
Objectives:	Graves’	 hyperthyroidism	 (GH)	 interferes	with	 iron	metabolism	 and	 ele-
vates	 ferritin.	 The	 precise	 mechanisms	 remain	 unclear.	 The	 influence	 of	 thyroid	
	hormones	 on	 the	 synthesis/regulation	 of	 hepcidin,	 an	 important	 regulator	 of	 iron	
	metabolism,	remains	uncharacterized.
Design:	Prospective	observational	study.
Patients:	We	included	patients	(n	=	31)	with	new-	onset	and	untreated	GH.
Measurements:	Laboratory	parameters	indicative	of	iron	metabolism	(ferritin,	trans-
ferrin,	hepcidin),	inflammatory	markers/cytokines	and	smoking	status	were	assessed	
at	the	diagnosis	of	GH	(T0)	and	at	euthyroidism	(T1)	in	the	same	patients	using	multi-
variable	 analyses.	 Hepcidin	 was	 measured	 by	 mass	 spectrometry	 (hepcidinMS)	 and	
ELISA	(hepcidinEL).	The	impact	of	T3	on	hepatic	hepcidin	expression	was	studied	in	a	
cell	culture	model	using	HepG2	cells.
Results:	Median	 ferritin	 levels	were	 significantly	 lower	 and	 transferrin	 significantly	
higher	 at	T1	 than	 at	T0.	HepcidinMS	 levels	were	 lower	 in	males	 and	 females	 at	T1	
	(statistically	significant	in	males	only).	No	statistically	significant	difference	in	hepcidi-
nEL	was	detected	between	T0	and	T1.	Plasma	levels	of	inflammatory	markers	(high-	
sensitive	 CRP,	 procalcitonin)	 and	 cytokines	 (interleukin	 6,	 interleukin	 1ß,	 tumour	
necrosis	 factor	α)	were	not	different	between	T0	and	T1.	Smokers	 tended	 to	have	
lower	fT3	and	fT4	at	T0	than	nonsmoking	GH	patients.	T3	significantly	induced	hepci-
din	mRNA	expression	in	HepG2	cells.
Conclusions:	Iron	metabolism	in	patients	with	GH	undergoes	dynamic	changes	in	pa-
tients	with	GH	that	resemble	an	acute-	phase	reaction.	Inflammatory	parameters	and	
cytokines	 were	 unaffected	 by	 thyroid	 status.	 Gender	 and	 smoking	 status	 had	 an	
	impact	on	ferritin,	hepcidin	and	thyroid	hormones.
K E Y W O R D S
ferritin,	Graves’	hyperthyroidism,	hepcidin,	iron	metabolism
1  | INTRODUCTION
Hyperthyroidism	 is	 a	 systemic	 disorder.	Apart	 from	well-	known	 im-
plications	of	thyroid	overfunction	for	example	on	the	cardiovascular	
system	and	bone	metabolism,	thyroid	hormone	excess	interferes	also	
with	iron	metabolism;	that	is,	it	elevates	ferritin	and	has	an	impact	on	
other	 haematologic	 parameters.	 These	 abnormalities	 are	 temporary	
and	normalize	once	the	patient	has	achieved	an	euthyroid	state.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial-NoDerivs	License,	which	permits	use	and	distribution	in	any	
medium,	provided	the	original	work	is	properly	cited,	the	use	is	non-commercial	and	no	modifications	or	adaptations	are	made.
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In	 severe	 hyperthyroidism	 normochromic,	 normocytic	 anaemia	
may	be	associated	with	impaired	iron	use.1,2	These	anaemias	are	un-
responsive	to	haematinic	 therapy2	 (ie	substitution	with	 iron,	vitamin	
B12	or	 folate)	 and	vanish	 once	 normal	 thyroid	 function	 is	 restored.	
On	the	other	hand,	there	are	manifold	effects	of	thyroid	hormones	on	
iron	metabolism.
Iron	acts	as	an	important	cofactor	in	fundamental	biochemical	pro-
cesses,	for	example	oxygen	transport.	High	iron	concentrations	are	toxic,	
and	therefore,	iron	metabolism	in	the	body	is	highly	regulated.	Several	
proteins	play	a	critical	role	in	iron	metabolism.	Iron,	bound	to	transferrin,	
is	transported	within	the	plasma	and	internalized	by	receptor-	mediated	
endocytosis.	 Intracellular	 ferritin	 is	 principally	 responsible	 for	 storage	
and	buffering	of	excess	iron.3 Hepcidin,	a	liver-	derived	peptide	hormone,	
is	one	of	the	most	important	regulators	of	iron	homeostasis.	It	 lowers	
plasma	iron	by	downregulating	ferroportin	1	(FPN-	1),	which	promotes	
iron	 efflux	 out	 of	 cells	 (enterocytes,	 hepatocytes	 or	macrophages).4,5 
The	bioactive	form	of	hepcidin	(hepcidin-	25)	contains	25	amino	acids.	
Smaller	 isoforms	 (hepcidin-	24,	 hepcidin-	23,	 hepcidin-	22)	 are	 usually	
present	in	conditions	characterized	by	elevated	hepcidin-	25	levels;	how-
ever,	the	biological	significance	of	these	isoforms	remains	unclear.6-8
Acute-	phase	reactions	lead	to	substantial	changes	in	iron	metab-
olism	and	are	characterized	by	high	levels	of	ferritin	and	hepcidin	and	
low	levels	of	iron	and	transferrin.3	Animal	models	of	hyperthyroidism	
demonstrate	decreased	circulating	plasma	iron	and	increased	hepatic	
iron	and	ferritin.	In	addition,	hepatic	ferritin	synthesis	is	increased,	al-
though	hepatic	 albumin	 synthesis	 remains	unchanged.9	 In	hyperthy-
roid	states,	plasma	erythropoietin	(EPO)	levels	are	high,	erythropoiesis	
is	increased,	and	bone	marrow	is	hypercellular.2,10,11	Hence,	iron	turn-
over	due	to	augmented	iron	utilization	is	increased,	but	iron	overload	is	
absent,2,10,12	and	the	concomitant	expansion	of	plasma	volume	masks	
the	increase	in	red	blood	cell	mass.12	The	observed	decline	in	plasma	
iron	levels	can	be	explained	by	faster	incorporation	of	iron	into	haeme;	
however,	any	impact	of	hepcidin	remains	speculative	because	there	are	
no	data	regarding	the	influence	of	thyroid	hormones	on	hepcidin	syn-
thesis	and	regulation.	Case	reports	and	case	series	have	described	tran-
siently	elevated	ferritin	levels	in	hyperthyroid	patients	that	decreased	
after	achieving	a	euthyroid	state.13-16	Whereas	some	studies	found	a	
positive	correlation	between	levels	of	thyroid	hormones	and	ferritin,15 
others	 did	 not.14	 Furthermore,	 the	mechanisms	 of	 hyperthyroidism-	
associated	hyperferritinaemia	remain	poorly	understood.
Here,	 we	 hypothesize	 that	 thyroid	 hormones	 directly	 influence	
iron	metabolism	by	affecting	ferritin	and/or	hepcidin	levels.	Therefore,	
the	aims	of	this	study	were	as	follows:
•	 To	 quantify	 the	 levels	 of	 ferritin,	 hepcidin	 and	 other	 parameters	
related	to	iron	metabolism	(eg	transferrin)	in	patients	with	Graves’	
hyperthyroidism	 (GH)	 and	 in	 the	 same	 patients	 after	 they	 had	
achieved	euthyroidism.
•	 To	 investigate	 potential	 mechanisms	 by	 measuring	 inflammatory	
parameters	and	cytokines	and	to	set	these	measurements	in	rela-
tion	to	gender	and	smoking	status.
•	 To	 study	 the	 impact	 of	 thyroid	 hormones	 on	 hepatic	 hepcidin	
	expression	using	a	cell	culture	model.
2  | SUBJECTS AND METHODS
This	was	a	prospective	observational	study.	The	subjects	consisted	of	
patients	who	attended	our	outpatient	clinic	with	newly	diagnosed	and	
untreated	Graves’	 hyperthyroidism	 (GH).	 Exclusion	 criteria	were	 the	
following:	age	below	18	years,	pregnancy/planned	pregnancy,	known	
hepatopathy,	 alcohol	 abuse	 (defined	as	 consumption	of	≥3	 standard	
drinks	 per	 day	 in	 females	 or	 ≥4	 standard	 drinks	 per	 day	 in	 males),	
known/treated	iron	deficiency,	active	malignancy,	chronic	renal	insuf-
ficiency	 (≥	 chronic	kidney	disease	 stage	 III)	 and	acute/chronic	 infec-
tions.	Laboratory	parameters	were	assessed	in	patients	at	the	diagnosis	
of	GH	 (T0)	and	after	 they	 reached	euthyroid	 function	 (T1)	 following	
treatment	with	 antithyroid	 therapy	 (carbimazole	 or	 propylthiouracil).	
Euthyroid	 function	was	 defined	 as	 the	 presence	 of	 normal	 thyroid-	
stimulating	hormone	(TSH)/free	triiodothyronine	(fT3)	and	free	thyrox-
ine	 (fT4)	values	 for	at	 least	4	weeks.	Thyroid	volume	was	calculated	
using	B-	mode	standard	ultrasonography.	All	patients	gave	their	written	
informed	consent.	The	study	conformed	to	the	declaration	of	Helsinki	
and	was	 approved	 by	 the	 local	 ethics	 committee	 (approval	 number:	
EKNZ-	13077).
2.1 | Laboratory assessment
Indicators	of	 thyroid	 function	 (TSH,	 fT3,	 fT4,	anti-	TSH-	receptor	an-
tibodies),	 iron	 metabolism	 (ferritin,	 transferrin,	 iron,	 soluble	 trans-
ferrin	 receptor	 [sTfR])	 and	 inflammation	 (high-	sensitive	 c-	reactive	
protein	 [hsCRP],	 procalcitonin)	 were	 measured	 using	 electrochemi-
luminescence	immunoassays	(ECLIA,	Roche	COBAS®	System,	Roche	
Diagnostics,	 Rotkreuz,	 Switzerland).	 Ferritin	 index	 was	 calculated	
using	the	quotient	of	sTfR/log	ferritin.
Aliquots	were	kept	at	−70°C	for	batch	analysis	of	hepcidin	and	cy-
tokines.	Hepcidin	analyses	were	performed	using	two	different	assays:	
mass	 spectrometry	 for	 the	 determination	 of	 bioactive	 hepcidin-	25	
(hepcidinMS),	 which	 represents	 the	 most	 specific	 and	 accurate	 ap-
proach	for	detecting	bioactive	hepcidin.6,8,17	For	comparison,	hepcidin	
was	also	measured	by	ELISA	(hepcidinEL,	Hepc	Cusabio
®,	College	Park,	
MD,	USA),	which	 detects	 hepcidin-	25	 and	 other	 hepcidin	 	isoforms.	
Measurement	 of	 cytokines	 was	 performed	 using	 a	 flowcytometric	
method.
2.2 | Cell culture
HepG2	 cells	 were	 cultured	 in	 Dulbecco’s	 modified	 Eagle’s	 medium	
(DMEM)	 (1	g/L	 glucose)	 supplemented	 with	 10%	 foetal	 bovine	
serum	and	1%	penicillin/streptomycin.	For	gene	expression	analysis,	
2	×	105	cells/well	were	seeded	into	six-	well	plates.	After	attachment,	
cells	were	washed	in	phosphate-	buffered	saline	(PBS)	and	incubated	
in	serum-	free	DMEM	for	24	hours.	Thereafter,	cells	were	stimulated	
with	±10	nmol	L−1	T3	(Sigma-	Aldrich,	Buchs,	Switzerland)	for	24	hours	
in	 serum-	free	DMEM.	After	washing	with	PBS,	RNA	was	extracted	
(NucleoSpin®,	 Macherey-	Nagel,	 Düren,	 Germany)	 and	 reverse-	
transcribed	(Takara	Bio	Europe,	Saint-	Germain-	en-	Laye,	France),	and	
quantitative	 real-	time	PCR	was	performed	 as	described.18	Hepcidin	
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primers	(Hs00221783_m1)	were	purchased	from	Applied	Biosystems	
(ThermoFisher	Scientific,	Waltham,	MA,	USA).
2.3 | Statistical analysis
The	 values	 for	 each	 parameter	were	 compared	 at	 baseline	 (T0)	 and	
follow-	up	 (T1),	 as	 defined	 above.	 Initially,	 data	 were	 analysed	 de-
scriptively	by	calculating	medians	and	interquartile	ranges	(IQRs).	The	
statistical	 significance	 of	 any	 differences	 was	 established	 using	 the	
nonparametric	Wilcoxon	matched-	pairs	signed-	rank	test.	For	the	main	
variables	 (fT3,	 fT4,	 ferritin,	 hepcidin	 and	 transferrin),	 separate	multi-
variable	analyses	were	performed	using	 random-	effects	models	with	
a	random	intercept.	Standard	errors	were	estimated	with	the	Huber-	
White	 sandwich	method19	 because	of	observed	variance	heterosce-
dasticity.	Only	patients	without	missed	measurements	at	either	T0	or	
T1	were	included	in	the	regression	analysis.	Analyses	were	repeated	by	
TABLE  1 Thyroid	parameters,	mediators	of	iron	metabolism	and	inflammatory	markers
Parameter (unit) Reference range
n Complete measurement 
pairs (T0&T1) Baseline (T0) Follow- up (T1) P- valuea
TSH	(mU/L) 0.27-	4.2 31 <0.01 
(0.01-	0.01) 
[0.01-	0.02]
1.54 
(0.59-	2.74) 
[0.01-	6.11]
<.001
fT4	(pmol	L−1) 12.0- 22.0 31 35.3 
(26.7-	51.9) 
[12.3-	100.1]
13.8 
(11.1-	15.0) 
[7.8-	22.0]
<.001
fT3	(pmol	L−1) 3.1-	6.8 31 13.8 
(9.0-	23.1) 
[4.3-	30.8]
4.4 
(4.1-	5.0) 
[2.6-	6.7]
<.001
TRAb	(U/L) <1.8 31 6.2 
(2.8-	12.2)
1.5 
(0.5-	4.0)
<.001
Plasma	Iron	(μmol	L−1) F:	6.6-	26 
M: 11- 28
31 16.8 
(9.2-	21.9)
19.1 
(16.3-	23.3)
.143
Transferrin	(g/L) 2.0-	3.6 31 2.3 
(2.1-	2.5)
2.6 
(2.4-	2.8)
.002
Transferrin	Saturation	(%) 16-	45 31 30.3 
(20.3-	42.0)
31.8 
(23.5-	38.3)
.7
Soluble	Tf-	receptor	(mg/L) F:	1.9-	4.4 
M:	2.2-	5.0
31 2.4 
(2.1-	2.9)
2.7 
(2.2-	3.4)
.138
Ferritin	(μg/L) Fb:	23-	160 
Fc:	30-	400 
M:	30-	400
31 156.0 
(63-	262)
80.0 
(38-	141)
.015
HepcidinMS	(nmol	L
−1) Fb:	0.4-	9.2 
Fc: 0.7- 16.2 
M:	1.1-	15.6
25 9.0 
(6.5-	17.1)
5.9 
(4.3-	7.6)
.011
HepcidinEL	(ng/mL) 4.69-	300
d 25 185 
(108-	277)
115 
(63.75-	178.5)
.0533
hsCRP	(mg/L) <5 31 1.3 
(0.4-	4.6)
0.9 
(0.3-	3.1)
.750
PCT	(μg/L) <0.1 31 0.04 
(0.04-	0.05)
0.04 
(0.03-	0.05)
.163
IL-	1β	(pg/mL) 0.0-	3.9 30 0.10 
(0.00-	0.25)
0.05 
(0.00-	0.48)
.838
IL-	6	(pg/mL) 0.0-	3.1 30 2.00 
(1.40-	3.45)
1.45 
(0.90-	3.13)
.248
TNF-	α	(pg/mL) 0.0-	6.3 30 0.00 
(0.00-	0.45)
0.25 
(0.00-	0.60)
.233
Values	expressed	as	median	(IQR)¸	([range]	thyroid	function	tests).
TSH,	Thyroid-	stimulating	hormone;	fT4,	Free	T4;	fT3,	Free	T3;	TRAb,	Thyroid	receptor	antibodies;	HepcidinMS,	Hepcidin-	25	determined	by	mass	spectrom-
etry;	HepcidinMS,	Hepcidin	determined	by	ELISA;	F,	reference	range	for	females;	M,	reference	range	for	males.
aDifference	between	baseline	(T0)	and	follow-	up	(T1)	by	Wilcoxon	signed-	rank	test.
bReference	range	for	females	18-	50	years.
cReference	range	for	females	>50	years.
dNo	gender-	/age-	specific	reference	ranges	available.
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including	also	patients	with	partially	missing	data	(hepcidin	could	not	
be	measured	in	six	patients	at	T0,	one	patient	had	no	measurements	of	
cytokines	at	T0),	with	no	alteration	of	the	results	or	conclusions.
The	main	 exposure	 of	 interest	 in	 our	multivariable	 analysis	was	
the	time	point	(baseline	T0	or	follow-	up	T1).	The	following	variables	
were	considered	 for	model	adjustment:	 age,	gender,	 smoking	status	
and	time	between	baseline	and	follow-	up	(in	days).	We	also	tested	for	
interactions	with	gender	and	smoking	status.	These	interaction	tests	
were	 specified	 a	 priori	 and	were	 based	 on	 existing	 evidence	 in	 the	
literature.	The	variables	were	manually	added	to	the	model	in	an	incre-
mental	fashion,	and	the	results	were	inspected	visually.	The	final	mod-
els	only	included	those	adjustments	that	exerted	a	substantial	impact	
on	the	point	estimate	for	the	time	point	(>20%)	and	interaction	terms	
with	P	<	.1.	All	data	analyses	were	performed	using	Stata	SE	version	
13.1	(StataCorp	LLC,	College	Station,	TX,	USA).	Statistical	significance	
was	defined	as	P	<	.05.	All	tests	were	two-	sided.	No	adjustments	for	
multiple	testing	were	performed.
3  | RESULTS
Thirty-	one	patients	(22	females,	nine	males;	mean	age	48	years	[range	
26-	82])	were	included	in	the	study.	Twelve	of	thirty-	one	(38%)	patients	
were	smokers.	The	median	(IQR)	thyroid	volume	was	13.9	(10.6-	23.1)	
mL,	 and	 thyroid	 parameters	 are	 displayed	 in	 Table	1.	 Patients	 were	
treated	 either	 with	 carbimazole	 (n	=	29)	 or	 propylthio	uracil	 (n	=	2).	
Two	patients	had	normochromic,	normocytic	anaemia	at	baseline	that	
resolved	 at	 T1,	 but	 none	had	 laboratory	 values	 consistent	with	 iron	
deficiency	(ie	ferritin	index	≥3	or	soluble	transferrin	receptor	>5	mg/L).
Restoring	 normal	 thyroid	 function	 led	 to	 a	 rise	 of	 transferrin 
and plasma iron	 (values	 for	 iron	at	T1	not	 significant).	By	contrast,	
transferrin	 saturation	 and	 soluble	 transferrin	 receptor	 levels	were	
unaffected	by	 thyroid	 function	as	were	plasma	 levels	of	 inflamma-
tory markers	(hsCRP	and	procalcitonin)	and	cytokines	(IL-	6,	IL-	1ß	and	
TNF-	α,	Table	1).	Smoking	status	had	no	impact	on	levels	of	 inflam-
matory	markers	and	cytokines	(data	not	shown).
Median	(IQR)	ferritin	concentrations	at	baseline	were	156	(63-	262)	
μg/L	and	were	higher	in	males	(277	[222.5-	615]	μg/L)	than	in	females	
(117.5	[56.75-	210]	μg/L).	The	highest	ferritin	values	were	1100	μg/L	
in	one	male	and	443	μg/L	in	one	female	patient	at	T0,	but	in	both	of	
these	patients	the	values	had	normalized	at	T1.	Median	ferritin	levels	
FIGURE 1 Change	in	serum	ferritin	levels	between	baseline	(T0)	and	
follow-	up	measurements	(T1).	Interaction	model	adjusted	for	sex	and	
age	at	baseline	(time	between	measurements	and	smoking	status	were	
also	considered)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
FIGURE 2 Change	in	serum	hepcidinMS	levels	between	baseline	(T0)	
and	follow-	up	measurements	(T1).	Interaction	model	adjusted	for	sex	and	
age	at	baseline	(time	between	measurements	and	smoking	status	were	
also	considered)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
F IGURE  3 Change	in	fT4	(A)	and	fT3	(B)	between	baseline	(T0)	
and	follow-	up	measurements	(T1),	showing	the	difference	between	
smokers	and	nonsmokers.	(A)	Test	for	interaction	between	time	and	
smoking	status	(suggesting	differences	in	the	dynamics	of	the	change	
according	to	smoking	status):	P	=	.011.	**P	=	.016	(Wald	test).	(B)	
Test	for	interaction	between	time	and	smoking	status	(suggesting	
differences	in	the	dynamics	of	the	change	according	to	smoking	
status):	P	=	.004.	**P	=	.006	(Wald	test)	[Colour	figure	can	be	viewed	
at	wileyonlinelibrary.com]
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decreased	 significantly	 after	 euthyroid	 function	 had	 been	 achieved	
(Table	1,	Figure	1).
Median	 (IQR)	 hepcidinMS	 concentrations	 at	 baseline	 were	 9.15	
(6.45-	17.25)	 nmol	L−1	 and	 were	 higher	 in	 males	 (17.1	 [10.5-	26.9]	
nmol	L−1)	 than	 in	 females	 (8.3	 [6.3-	13.6]	 nmol	L−1).	As	with	 ferritin,	
hepcidinMS	 levels	decreased	 in	males	and	 females	after	patients	had	
reached	euthyroidism.	This	change	was	only	statistically	significant	in	
men	(Table	1,	Figure	2).	Changes	between	T0	and	T1	did	not	reach	sta-
tistical	significance	when	hepcidin	was	measured	by	ELISA	(hepcidinEL,	
Table	1).	There	was	no	correlation	detected	between	anti-	TSH	recep-
tor	antibody	(TRAb)	titres	and	ferritin/hepcidin	levels	(data	not	shown).
3.1 | Multivariable regression analyses
The	 following	 four	parameters	were	 also	 subjected	 to	multivariable	
regression	analyses:	ferritin,	hepcidinMS,	fT3	and	fT4	(Table	2).	While	
the	patterns	of	change	observed	in	univariable	analyses	were	largely	
replicated,	multivariable	analyses	also	 indicated	confounding	by	age	
(ferritin)	and,	more	importantly,	effect	modification	by	smoking	status	
and	sex.	With	respect	to	the	latter,	the	changes	in	ferritin	and	hepcidin	
differed	significantly	between	males	and	females,	with	males	having	
higher	values	at	baseline	but	a	subsequent	steeper	decline.	At	follow-
	up,	the	differences	were	still	statistically	significant	between	the	two	
sexes	 for	 ferritin	 (estimated	 difference	 between	males	 and	 females	
TABLE  2 Multivariable	regression	analyses
Ferritin (μg/L) HepcidinMS (nmol L−1)
Univariable Multivariable Univariable Multivariable
Intercept 222.55 (142.10; 303.00) 205.80 (24.49; 387.11) 11.42 (8.42; 14.42) 18.32 (11.32; 25.32)
Age	at	baseline	 
(per	year	increase)
4.36 (0.67; 8.04)
Female	sex −259.29 (−450.93; −67.65) −9.07 (−16.57; −1.58)
Smoker
Time	between	T0	and	T1 −1.50 (−3.16; 0.16)
Change	from	T0	to	T1 −107.39 (−155.83; −58.94) −217.67 (−344.81; −90.52) −4.86 (−7.40; −2.33) −8.35 (−12.99; −3.71)
Interaction	of	T1	and	
female	sexa
155.39 (24.97; 285.82) 6.57 (1.21; 11.92)
Interaction	of	T1	and	
smokingb
fT3 (pmol L−1) fT4 (pmol L−1)
Univariable Multivariable Univariable Multivariable
Intercept 16.09 (13.17; 19.02) 18.47 (14.29; 22.64) 41.55 (33.70; 49.39) 48.58 (37.47; 59.70)
Age	at	baseline	(per	year	
increase)
Female	sex
Smoker −6.14 (−11.11; −1.16) −18.18 (−31.15; −5.21)
Time	between	T0	and	T1
Change	from	T0	to	T1 −11.55 (−14.54; −8.56) −14.05 (−18.36; −9.75) −27.90 (−35.56; −20.25) −34.89 (−45.85; −23.94)
Interaction	of	T1	and	 
female	sexa
Interaction	of	T1	and	
smokingb
6.47 (1.48; 11.47) 18.06 (5.63; 30.49)
Results	(95%	CI),	printed	in	italic	indicate	p	<	0.05.
aDifference	in	change	between	sexes.
bDifference	in	change	between	smokers	and	nonsmokers.
F IGURE  4 Hepcidin	mRNA	expression	in	HepG2	cells	stimulated	
with	T3	versus	control	(Co)	**P	<	0.01.
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[95%	confidence	interval	(CI)]:	103.9	μg/L	[22.9;	184.9]),	but	not	for	
hepcidin	(2.5	nmol	L−1	[−0.9;	6.0]).
Further,	 the	 regression	models	 for	 fT4	 and	 fT3	 indicated	differ-
ences	 in	 the	 dynamics	 of	 changes	 between	 smokers	 and	 nonsmok-
ers	(Figure	3a/b).	In	particular,	smokers	had	lower	fT3	and	fT4	at	T0	
(model	estimates	[95%	CI]	for	differences	between	nonsmokers	and	
smokers	 of	 −6.1	pmol	L−1	 [−11.1;	 −1.2]	 and	 −18.2	 pmol	L−1	 [−31.1;	
−5.2],	 respectively).	 During	 follow-	up,	 these	 laboratory	 parameters	
stabilized	 at	 similar	 levels	 for	 smokers	 and	 nonsmokers	 (differences	
of	0.3	pmol	L−1	[−0.2;	0.9]	and	−0.1	pmol	L−1	[−2.2;	2.0],	respectively).
3.2 | Cell culture model
To	investigate	whether	elevated	hepcidin	levels	in	hyperthyroid	sub-
jects	might	be	directly	 driven	by	high	 fT3	 levels,	 experiments	were	
performed	in	a	human	liver	cell	line.	As	shown	in	Figure	4,	T3	treat-
ment	significantly	induced	hepcidin	mRNA	expression	in	HepG2	cells,	
consistent	with	the	findings	in	patients.
4  | DISCUSSION
The	results	of	our	study	are	threefold:	(i)	GH	leads	to	changes	in	iron	
metabolism	that	 resemble	a	classical	 “acute-	phase	reaction,”	 that	 is,	
elevation	of	ferritin	and	hepcidin	and	a	decline	of	transferrin	and	iron	
levels.	These	changes	seem	to	be	(in	part)	independent	from	inflam-
matory	parameters	and	normalize	after	achieving	euthyroid	function.	
(ii)	There	is	an	impact	of	gender	and	smoking	status	on	these	param-
eters;	that	is,	ferritin	and	hepcidin	levels	are	influenced	by	gender,	fT3	
and	fT4	by	smoking	status.	(iii)	Thyroid	hormones	have	a	direct	impact	
on	hepcidin	mRNA	expression	in	the	cell	culture	model.
Regulation	of	the	synthesis	and	secretion	of	ferritin	and	hepcidin	is	
complex	and	involves	multiple	pathways	and	effectors,	including	total	
iron	content,	reactive	oxygen	species,	erythropoietin	(EPO)	levels	and	
cytokines.20	During	acute-	phase	reactions,	a	variety	of	cytokines	and	
pro-	inflammatory	molecules	(TNF-	α,	IL-	1α,	IL-	1β,	IL-	6,	lipopolysaccha-
ride	 and	 nitric	 oxide)	 regulate	 ferritin	 by	 inducing	 the	 transcription,	
stimulating	 the	 secretion	 and	 modulating	 the	 post-	transcriptional	
mechanisms.21	 IL-	6	is	one	of	the	primary	inducers	of	hepcidin22,23 in 
inflammatory	and	infectious	states.	In	contrast,	EPO	suppresses	hepci-
din	levels24;	however,	the	effect	of	the	high	EPO	levels	in	hyperthyroid	
patients10	on	hepcidin	synthesis	may	be	overridden	by	other	factors	
(eg	thyroid	hormones).
New-	onset	GH	can	be	interpreted	as	a	form	of	acute-	phase	or	in-
flammatory	 reaction,	but	markers	of	 inflammation	and	 inflammatory	
cytokines	 in	our	patients	were	not	affected	neither	by	thyroid	func-
tion	nor	by	 smoking	 status.	These	 findings	 are	 in	 concordance	with	
other	studies	where	circulating	serum	cytokines	are	unchanged	in	GH	
	patients25	or	only	partially	elevated.26
Therefore,	a	direct	hormonal	influence	on	the	physiology	of	ferritin	
and	hepcidin	must	be	assumed.	Cell	 culture	models	 indeed	demon-
strated	that	ferritin	gene	transcription	was	induced	by	insulin/IGF-	1,27 
TSH28	 and	 T329	 and	 that	 the	 latter	 modulates	 post-	transcriptional	
mechanisms	via	iron	regulatory	proteins	(IRPs).29	This	is	the	first	study	
to	show	a	direct	effect	of	T3	on	hepcidin	mRNA	expression	in	a	human	
liver	cell	line,	which	is	consistent	with	the	clinical	finding	of	elevated	
hepcidin	levels	in	our	hyperthyroid	subjects.	Of	note,	the	impact	of	T3	
stimulation	on	hepcidin	production	 in	HepG2	cells	was	assessed	on	
mRNA	but	not	on	protein	levels,	as	hepcidin	production	may	mainly	be	
regulated	at	transcriptional	level.30
In	our	study	population,	ferritin	and	hepcidin	levels	showed	wide	
variability	and	were	higher	 in	men	 than	 in	women.	The	 influence	of	
gender	on	ferritin31	and	hepcidin32	is	well	known.	Oestrogen	inhibits	
hepcidin	synthesis33	and	hepcidin	levels	are	lower	in	premenopausal	
subjects32	and	in	women	with	high	endogenous	oestrogen	levels	re-
sulting	from	in	vitro	fertilization	procedures.34	In	our	study,	the	major-
ity	(16/22)	of	the	female	patients	were	premenopausal	and	thus	had	
lower	hepcidin	levels,	which	may	have	contributed	to	the	difficulty	in	
detecting	differences	in	hepcidin	levels	between	T0	and	T1	in	female	
subjects.
Compared	 to	smokers,	nonsmokers	had	significantly	higher	 fT3	
and	fT4	values	at	T0.	Smoking	has	an	impact	on	various	aspects	of	
thyroid	function	and	the	development	of	thyroid	disease.35	Smokers	
are	exposed	to	higher	thiocyanate	levels,36	which	can	affect	T3	and	
T4	 concentrations,37	mainly	 through	 its	 inhibitory	 effect	 on	 iodine	
trapping.38	In	addition,	lower	T3	and	T4	levels	have	been	described	
in	smokers	with	normal	thyroid	function.39,40	However,	to	the	best	of	
our	knowledge,	the	impact	of	smoking	on	T3	and	T4	levels	in	patients	
with	hyperthyroidism	and	GH	has	not	been	described	until	now.
In	comparison	with	other	studies,13-16	 this	study	had	the	advan-
tages	 of	 including	 only	 patients	with	GH,	 using	 longitudinal	 assess-
ments	of	laboratory	values	and	measuring	a	novel	variable	related	to	
iron	metabolism	(hepcidin).	Our	study	design	allowed	us	to	compare	
and	 demonstrate	 the	 dynamic	 changes	 in	 ferritin	 and	 hepcidin	 that	
occur	in	the	same	individuals	during	thyroid	hyperfunction	and	after	
the	 achievement	of	 normal	 thyroid	 function.	This	 approach	 allowed	
the	elimination	of	high	interindividual	variability	in	ferritin	and	hepci-
din	levels.
Another	strength	of	our	study	was	the	use	of	mass	spectrometry,	
the	most	accurate	method	for	the	quantification	of	bioactive	hepcidin.	
A	recently	published	study34	found	no	differences	in	circulating	hepci-
din	levels	in	20	patients	with	hyperthyroidism	(17	with	GH,	two	with	
subacute	thyroiditis	and	one	with	toxic	nodular	goitre).	However,	hep-
cidin	levels	in	that	study	were	measured	by	ELISA	only,	which	has	the	
drawback	of	low	specificity	and	accuracy.	This	is	in	line	with	our	find-
ings	 showing	no	 statistically	 significant	differences	 in	hepcidin	 levels	
between	time	points	when	hepcidin	levels	were	measured	using	ELISA.
The	 study	 has	 two	 principal	 limitations:	 the	 sample	 size	 was	
small	and	only	 fraction	of	 the	 factors	 (eg	cytokines)	 that	are	known	
to	 	influence	the	 levels	of	proteins	 involved	 in	 iron	metabolism	were	
	measured.	Thus,	we	were	unable	to	elucidate	fully	the	complex	regula-
tion	of	iron	metabolism	in	hyperthyroid	patients.
From	a	clinical	point	of	view,	knowledge	of	these	dynamic	changes	
and	 the	 underlying	 mechanisms	 is	 critical,	 allowing	 the	 clinician	
to	 estimate	 the	 impact	 of	 thyroid	 function	 abnormalities	 on	 these	
	parameters,	 to	 consider	 other	 differential	 diagnoses	 and	 to	 prevent	
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unnecessary	investigations	(eg	for	clarification	of	hyperferritinaemia).	
The	role	of	these	acute-	phase	mechanisms	in	GH	in	the	clinical	con-
text	should	be	further	elucidated.	As	with	cytokines41	or	TRAb	titres,42 
hepcidin	and	ferritin	levels	could	have	a	potential	role	as	parameters	
for	predicting	relapse	of	GH	after	thyrostatic	treatment.	However,	this	
topic	has	to	be	clarified	in	future	studies.
In	 conclusion,	 our	 study	 results	 indicate	 that	 iron	metabolism	 in	
patients	with	GH	undergoes	dynamic	changes	that	are	comparable	to	
an	acute-	phase	 reaction.	Gender	and	smoking	status	had	an	 impact	
on	parameters	of	iron	metabolism	and	thyroid	hormones,	in	contrast	
to	inflammatory	parameters	and	cytokines,	which	were	unaffected	by	
thyroid	status.	For	 the	 first	 time,	we	were	able	 to	demonstrate	 that	
hepcidin,	 a	 key	 regulator	 of	 human	 iron	 metabolism,	 is	 affected	 in	
Graves’	hyperthyroidism	and	that	thyroid	hormones	had	a	direct	effect	
on	expression	of	this	protein	in	hepatocytes.
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